GO:0004711 ribosomal protein S6 kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004711 (ribosomal protein S6 kinase activity) is a molecular function defined as catalysis of the reaction: ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP.
• The founding enzymes are the p70 ribosomal protein S6 kinases (S6K1/RPS6KB1 and S6K2/RPS6KB2), which are activated downstream of mTOR and phosphorylate ribosomal protein S6 (RPS6).
• S6K1 signaling controls the ribosome biogenesis transcriptional program, linking this kinase activity to cell growth and size control.
• RPS6KB1 variants have been reported in hypertrophic cardiomyopathy, showing that this activity is relevant to human cardiac disease.
• S6K1 signaling in the prefrontal cortex controls depressive behavior in animal models, connecting this molecular function to neuropsychiatric biology.
• Small-molecule inhibitors of ribosomal protein S6 kinase 2 (lapachol) suppress growth and induce intrinsic apoptosis in esophageal squamous cell carcinoma cells.
Description
GO:0004711, ribosomal protein S6 kinase activity, is a molecular function in which an enzyme catalyzes the transfer of the gamma-phosphate of ATP to ribosomal protein S6, producing phosphorylated ribosomal protein S6 and ADP. This activity is best known as the output of the p70 S6 kinase (S6K) branch of the mTOR signaling network, where S6K1 and S6K2 phosphorylate RPS6 in response to growth factor and nutrient signals. Because the reaction directly modifies a core component of the 40S ribosomal subunit, it sits at the interface between signal transduction and the protein synthesis machinery. The functional importance of GO:0004711 extends beyond a single phosphorylation event. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program, meaning that the kinase output feeds back onto the expression of the machinery that builds ribosomes. This places the activity at the center of cell size control, proliferation, and metabolic adaptation. In vivo, manipulation of S6K1 signaling in the prefrontal cortex alters depressive behavior, demonstrating that this molecular function has behavioral consequences. For researchers, GO:0004711 is a tractable molecular function to interrogate with CRISPR-based models. Genetic variants in RPS6KB1 have been linked to hypertrophic cardiomyopathy, and pharmacological inhibition of ribosomal protein S6 kinase 2 suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells. These findings make the activity a candidate target for both mechanistic studies and therapeutic hypothesis testing.
ribosomal protein S6 kinase activity At A Glance
| GO ID | GO:0004711 |
|---|---|
| GO term | ribosomal protein S6 kinase activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Definition | Catalysis of the reaction: ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP. |
| Major function | Phosphorylation of ribosomal protein S6, linking growth signaling to ribosome biogenesis and cell size control. |
| Representative enzymes | RPS6KB1 (S6K1) and RPS6KB2 (S6K2). |
| Upstream regulator | mTOR signaling, including TSC2-dependent control of mTOR. |
| Substrate | Ribosomal protein S6 (RPS6). |
What Is GO:0004711?
In simple terms, GO:0004711 describes the enzyme activity that puts a phosphate group onto ribosomal protein S6 using ATP. Formally, it is the catalysis of the reaction: ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP, as defined in QuickGO. The activity is attributed to the p70 ribosomal protein S6 kinases, which are downstream effectors of mTOR signaling and are among the best-characterized kinases acting on RPS6.
Why Is ribosomal protein S6 kinase activity Important in Cell Biology?
GO:0004711 is important because it converts nutrient and growth-factor signals into a direct covalent modification of the translation machinery, thereby influencing cell size, proliferation, and ribosome biogenesis. Dysregulation of this activity has been associated with human disease, including hypertrophic cardiomyopathy linked to RPS6KB1 variants and cancer-related phenotypes in which S6K inhibition suppresses growth and induces apoptosis. Because the activity is enzymatically defined and genetically tractable, it is a practical entry point for CRISPR knockout, point-mutation, and knock-in studies of signaling and disease.
• Defines a specific enzymatic reaction that modifies ribosomal protein S6, a core 40S ribosomal subunit protein.
• Connects mTOR signaling to ribosome biogenesis and cell size control.
• RPS6KB1 variants have been reported in hypertrophic cardiomyopathy.
• S6K1 signaling in the prefrontal cortex controls depressive behavior in animal models.
• Ribosomal protein S6 kinase 2 inhibition suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells.
• RSK4, a related ribosomal S6 kinase family member, has prominent roles in cancer.
• Provides a measurable phosphorylation readout for pathway perturbation experiments.
• Is amenable to pharmacological and genetic interrogation in cell and animal models.
• Links nutrient sensing to the ribosome biogenesis transcriptional program.
• Supports hypothesis-driven CRISPR model design for cardiac, neuropsychiatric, and oncologic research.
Molecular Mechanism of ribosomal protein S6 kinase activity
Substrate recognition and phosphorylation of RPS6
In simple terms: The kinase finds ribosomal protein S6 and attaches a phosphate to it.
GO:0004711 is defined by the reaction ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP, meaning the enzyme transfers phosphate from ATP to ribosomal protein S6. The p70 S6 kinases are the canonical enzymes carrying this activity, and their phosphorylation of RPS6 is a widely used readout of mTOR-dependent signaling.
Upstream activation by mTOR signaling
In simple terms: A growth-signal pathway switches the kinase on.
S6K1 is activated downstream of mTOR, and TSC2 is phosphorylated and inhibited by Akt, which suppresses mTOR signaling and thereby reduces S6K1 output. This places GO:0004711 under the control of a well-defined growth-factor-responsive cascade.
Coupling to ribosome biogenesis transcription
In simple terms: The kinase signal tells the cell to build more ribosomes.
Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program, so the phosphorylation event is functionally coupled to expression of the machinery required for ribosome production. This coupling helps explain why the activity is associated with cell size control.
Pharmacological inhibition of S6 kinase activity
In simple terms: Drugs can block this kinase and change cell behavior.
Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells, demonstrating that the activity can be targeted pharmacologically. This provides a chemical complement to genetic approaches for studying GO:0004711.
Physiological and behavioral output
In simple terms: Changing this kinase activity can change behavior in animals.
Ribosomal protein S6 kinase 1 signaling in the prefrontal cortex controls depressive behavior, showing that the molecular function has systems-level consequences. This supports the use of GO:0004711 as a mechanistic node linking signaling to neuropsychiatric phenotypes.
Key Genes Involved in GO:0004711 ribosomal protein S6 kinase activity
The following genes and proteins are directly or functionally associated with ribosomal protein S6 kinase activity (GO:0004711) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RPS6KB1 | Encodes p70 S6 kinase 1 (S6K1), a principal enzyme with ribosomal protein S6 kinase activity. | Variants cause hypertrophic cardiomyopathy; central to mTOR-dependent cell size control. |
| RPS6KB2 | Encodes p70 S6 kinase 2 (S6K2), a ribosomal protein S6 kinase. | Target of lapachol; inhibition suppresses growth and induces apoptosis in esophageal squamous cell carcinoma cells. |
| RPS6 | Ribosomal protein S6, the substrate phosphorylated by GO:0004711. | Phospho-RPS6 is a widely used readout of S6K activity. |
| TSC2 | Tumor suppressor phosphorylated and inhibited by Akt, suppressing mTOR signaling. | Upstream negative regulator of the pathway feeding into S6K1. |
| AKT1 | Kinase that phosphorylates and inhibits TSC2, thereby influencing mTOR and S6K1. | Connects growth factor signaling to GO:0004711 output. |
| MTOR | Kinase upstream of S6K1 activation. | Central node controlling ribosomal protein S6 kinase activity. |
| RPS6KA6 | Encodes RSK4, a ribosomal S6 kinase family member. | Prominent roles in cancer. |
| RPS6KA1 | Ribosomal S6 kinase family member (RSK1). | Family context for S6 kinase biology. |
| RPS6KA2 | Ribosomal S6 kinase family member (RSK2). | Family context for S6 kinase biology. |
| RPS6KA3 | Ribosomal S6 kinase family member (RSK3). | Family context for S6 kinase biology. |
| RPS6KA4 | Ribosomal S6 kinase family member (RSK4 alias). | Family context for S6 kinase biology. |
| RPS6KA5 | Ribosomal S6 kinase family member (MSK1). | Family context for S6 kinase biology. |
| RPS6KA6 | Ribosomal S6 kinase family member (RSK4). | Cancer relevance. |
| APLN | Encodes apelin, an exerkine that reverses age-associated sarcopenia. | Exercise-linked regulator of muscle biology relevant to S6 kinase signaling. |
| APLNR | Apelin receptor mediating apelin effects. | Context for apelin biology in aging muscle. |
How Is ribosomal protein S6 kinase activity Regulated?
Ribosomal protein S6 kinase activity is regulated by the mTOR signaling axis. TSC2 is phosphorylated and inhibited by Akt, which suppresses mTOR signaling and thereby reduces S6K1 activation. This places GO:0004711 under the control of growth factor and nutrient inputs that converge on mTOR. In addition, the activity is coupled to the ribosome biogenesis transcriptional program, providing a feedback layer that links the phosphorylation event to expression of ribosome production genes. Pharmacological inhibition of ribosomal protein S6 kinase 2 by lapachol demonstrates that the activity can be blocked chemically, which is useful for dissecting pathway dependencies.
ribosomal protein S6 kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RPS6KB1 | Hypertrophic cardiomyopathy | Knock-in of patient variants in cardiomyocytes or animal models |
| RPS6KB2 | Esophageal squamous cell carcinoma growth and apoptosis | Knockout or point-mutation in carcinoma cell lines with lapachol treatment |
| RPS6KA6 | Cancer | Overexpression and knockout in cancer cell lines |
| RPS6KB1 | Depressive behavior via prefrontal cortex signaling | Region-specific knockout or knock-in in rodent models |
| APLN/APLNR | Age-associated sarcopenia | Knockout or overexpression in muscle models |
Hypertrophic cardiomyopathy
Ribosomal protein S6 kinase beta-1 gene variants cause hypertrophic cardiomyopathy, directly linking RPS6KB1 and the GO:0004711 activity to a human cardiac disorder. This finding supports genetic testing and mechanistic studies of S6K1 signaling in cardiomyocyte biology.
Cancer growth and apoptosis
Lapachol, a novel ribosomal protein S6 kinase 2 inhibitor, suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells, indicating that GO:0004711 can be a vulnerability in some tumors. RSK4, another ribosomal S6 kinase family member, has prominent roles in cancer, further supporting the disease relevance of this kinase family.
Neuropsychiatric and behavioral phenotypes
Ribosomal protein S6 kinase 1 signaling in the prefrontal cortex controls depressive behavior, showing that perturbation of this activity can produce behavioral changes in animal models. This connects GO:0004711 to neuropsychiatric research beyond its classical growth-control roles.
Aging and muscle biology
The exerkine apelin reverses age-associated sarcopenia, a process that intersects with growth and mTOR-related signaling. While the cited study focuses on apelin, it provides context for how S6 kinase-related pathways may be studied in aging muscle.
From ribosomal protein S6 kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RPS6KB1 reduce ribosomal protein S6 phosphorylation? | CRISPR knockout of RPS6KB1 in a relevant cell line |
| Do patient variants in RPS6KB1 alter kinase output? | Point-mutation knock-in of the variant |
| Can a tagged S6K1 be used to measure pathway dynamics? | Tagged knock-in of RPS6KB1 |
| Does overexpression of S6K2 change growth or apoptosis? | Overexpression of RPS6KB2 in carcinoma cells |
| Does S6K1 signaling in the prefrontal cortex affect behavior? | Region-specific knockout or overexpression in rodent models |
| Does inhibition of S6 kinase alter ribosome biogenesis transcription? | Pharmacological inhibition combined with knockout models |
How to Study the ribosomal protein S6 kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-RPS6 immunoblotting | Level of phosphorylated ribosomal protein S6 | Confirming S6K activity changes after perturbation |
| RNA-seq | Transcriptional changes including ribosome biogenesis genes | Assessing downstream program of S6 kinase activity |
| Cell viability and apoptosis assays | Growth suppression and intrinsic apoptosis | Testing S6K2 inhibitors such as lapachol |
| Behavioral testing in rodents | Depressive-like behavior | Evaluating prefrontal cortex S6K1 signaling |
| Muscle physiology assays | Sarcopenia-related parameters | Studying apelin and aging muscle |
| Genetic variant analysis | Association of RPS6KB1 variants with disease | Clinical genetics of hypertrophic cardiomyopathy |
| Kinase inhibitor profiling | Sensitivity of cells to S6 kinase inhibition | Cancer cell line screens |
| Cancer phenotyping | Roles of RSK4 in cancer | Functional studies of ribosomal S6 kinase family |
Phospho-RPS6 immunoblotting and immunofluorescence
Because GO:0004711 produces phosphorylated ribosomal protein S6, phospho-specific antibodies against RPS6 are a standard readout of the activity. This method is used to confirm whether genetic or pharmacological perturbations change S6K output.
Transcriptomic analysis of ribosome biogenesis
Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program, so RNA-seq or targeted expression panels can measure downstream transcriptional consequences of perturbing the activity. This links the molecular function to a broader gene expression program.
Pharmacological inhibition assays
Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells, providing a chemical tool for probing the activity. Such assays are typically combined with viability and apoptosis measurements.
Behavioral and physiological phenotyping
Ribosomal protein S6 kinase 1 signaling in the prefrontal cortex controls depressive behavior, so behavioral tests in rodent models are used to assess systems-level consequences of manipulating the activity. Similarly, muscle physiology studies can assess aging-related phenotypes in the context of apelin biology.
How CRISPR Can Be Used to Study GO:0004711 ribosomal protein S6 kinase activity
Knockout
CRISPR knockout of RPS6KB1 or RPS6KB2 can be used to test whether loss of the enzyme reduces ribosomal protein S6 phosphorylation and downstream ribosome biogenesis transcription. Such models are also useful for validating whether a disease-associated phenotype depends on the kinase activity.
Point Mutation
Point-mutation knock-in can introduce disease-associated variants such as those reported in RPS6KB1 in hypertrophic cardiomyopathy, allowing researchers to test whether the variant alters kinase output or cellular phenotypes. This approach is well suited to separating catalytic from non-catalytic functions.
Knock-in
Tagged knock-in of RPS6KB1 or RPS6KB2 enables tracking of the endogenous kinase and measurement of pathway dynamics without overexpression artifacts. Knock-in can also be used to place reporter or affinity tags under endogenous regulatory control.
Overexpression
Overexpression of RPS6KB2 or related ribosomal S6 kinases can be used to test sufficiency for growth, apoptosis, or cancer phenotypes. Overexpression models complement loss-of-function studies by revealing gain-of-function effects.
How EDITGENE Supports ribosomal protein S6 kinase activity Research
Researchers studying ribosomal protein S6 kinase activity-related genes often need to determine whether a candidate gene is causally involved in a signaling or disease phenotype, and CRISPR-based models provide a direct way to test that causality. By combining knockout, point-mutation, knock-in, and overexpression strategies, it becomes possible to dissect the contribution of GO:0004711 to cell growth, ribosome biogenesis, and disease.
Contact EDITGENE today to design your custom CRISPR model for ribosomal protein S6 kinase activity research.
Frequently Asked Questions About ribosomal protein S6 kinase activity
What is ribosomal protein S6 kinase activity?
It is the enzyme activity defined by GO:0004711 that catalyzes the reaction ribosomal protein S6 + ATP = ribosomal protein S6 phosphate + ATP.
What genes are involved in ribosomal protein S6 kinase activity?
Key genes include RPS6KB1 and RPS6KB2, which encode p70 S6 kinases, and RPS6, which encodes the substrate ribosomal protein S6.
What is the GO ID for ribosomal protein S6 kinase activity?
The GO ID is GO:0004711.
How is ribosomal protein S6 kinase activity regulated?
It is regulated by mTOR signaling, with TSC2 phosphorylated and inhibited by Akt, which suppresses mTOR and reduces S6K1 activation.
What diseases are linked to ribosomal protein S6 kinase activity?
RPS6KB1 variants cause hypertrophic cardiomyopathy, and S6K2 inhibition suppresses growth and induces apoptosis in esophageal squamous cell carcinoma cells.
Does ribosomal protein S6 kinase activity affect behavior?
Yes, S6K1 signaling in the prefrontal cortex controls depressive behavior in animal models.
What is the substrate of ribosomal protein S6 kinase activity?
The substrate is ribosomal protein S6, which is phosphorylated using ATP.
Can ribosomal protein S6 kinase activity be inhibited pharmacologically?
Yes, lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells.
How do researchers measure ribosomal protein S6 kinase activity?
Common approaches include phospho-RPS6 immunoblotting and transcriptomic analysis of the ribosome biogenesis program.
What CRISPR models are used to study ribosomal protein S6 kinase activity?
Knockout, point-mutation, knock-in, and overexpression models of RPS6KB1, RPS6KB2, and related genes are used to test causality and mechanism.
Conclusion
GO:0004711, ribosomal protein S6 kinase activity, is a well-defined molecular function that links growth signaling to phosphorylation of ribosomal protein S6 and to the ribosome biogenesis transcriptional program. Its relevance spans cardiac disease, cancer, and neuropsychiatric phenotypes, as shown by RPS6KB1 variants in hypertrophic cardiomyopathy, S6K2 inhibition in esophageal squamous cell carcinoma cells, and S6K1-dependent depressive behavior. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide a direct route to test how this activity contributes to normal physiology and disease.
References
- 1. Jain PK et al.. 2022. Ribosomal protein S6 kinase beta-1 gene variants cause hypertrophic cardiomyopathy.. J Med Genet 59(10):984-992 PMID: 34916228
- 2. Vinel C et al.. 2018. The exerkine apelin reverses age-associated sarcopenia.. Nat Med 24(9):1360-1371 PMID: 30061698
- 3. Inoki K et al.. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.. Nat Cell Biol 4(9):648-57 PMID: 12172553
- 4. Meyuhas O et al.. 2009. Ribosomal protein S6 kinase from TOP mRNAs to cell size.. Prog Mol Biol Transl Sci 90:109-53 PMID: 20374740
- 5. Zu X et al.. 2019. Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells.. Phytother Res 33(9):2337-2346 PMID: 31225674
- 6. Xu J et al.. 2021. Prominent roles of ribosomal S6 kinase 4 (RSK4) in cancer.. Pathol Res Pract 219:153374 PMID: 33621918
- 7. Dwyer JM et al.. 2015. Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.. Proc Natl Acad Sci U S A 112(19):6188-93 PMID: 25918363
- 8. Chauvin C et al.. 2014. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program.. Oncogene 33(4):474-83 PMID: 23318442
